Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

TELA Bio (TELA) EBITDA Margin (2018 - 2025)

TELA Bio has reported EBITDA Margin over the past 8 years, most recently at 43.32% for Q4 2025.

  • Quarterly results put EBITDA Margin at 43.32% for Q4 2025, up 918.0% from a year ago — trailing twelve months through Dec 2025 was 48.37% (up 623.0% YoY), and the annual figure for FY2025 was 48.37%, up 623.0%.
  • EBITDA Margin for Q4 2025 was 43.32% at TELA Bio, down from 41.59% in the prior quarter.
  • Over the last five years, EBITDA Margin for TELA hit a ceiling of 34.06% in Q1 2024 and a floor of 123.69% in Q1 2021.
  • Median EBITDA Margin over the past 5 years was 77.19% (2024), compared with a mean of 76.45%.
  • Biggest five-year swings in EBITDA Margin: skyrocketed 6936bps in 2021 and later tumbled -2676bps in 2025.
  • TELA Bio's EBITDA Margin stood at 91.4% in 2021, then grew by 11bps to 81.22% in 2022, then grew by 6bps to 76.09% in 2023, then soared by 31bps to 52.51% in 2024, then rose by 17bps to 43.32% in 2025.
  • The last three reported values for EBITDA Margin were 43.32% (Q4 2025), 41.59% (Q3 2025), and 49.12% (Q2 2025) per Business Quant data.